Shares of Genzyme Corp. continued climbing Thursday amid rumblings of a possible $70-per-share bid from Sanofi-Aventis SA, but whether $18.7 billion is a fair takeout price for the Cambridge, Mass.-based biotech clearly remains up for debate. (BioWorld Today) Read More
